(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)
(BIO101-COVA) Adaptive design phase 2 to 3, randomized, double-blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)
This study is for adults ages 18 and older who have a severe COVID-19 infection. The purpose is to see if a drug, Leronlimab (PRO 140), is a safe and effective treatment.
To be eligible, subjects must
* be 18 of age or older
* have a confirmed diagnosis of SARS-CoV-2
* be hospitalized
* be free of other serious or underlying health conditions or recent history of health events